|1.||Hattori, Kazuo: 2 articles (09/2003 - 03/2003)|
|2.||Miwa, Masanori: 2 articles (09/2003 - 03/2003)|
|3.||Eda, Hiroyuki: 2 articles (09/2003 - 03/2003)|
|4.||Ishikawa, Tohru: 2 articles (09/2003 - 03/2003)|
|5.||Ura, Masako: 2 articles (09/2003 - 03/2003)|
|6.||Ishitsuka, Hideo: 2 articles (09/2003 - 03/2003)|
|7.||Shimma, Nobuo: 2 articles (09/2003 - 03/2003)|
|8.||Tanimura, Hiromi: 2 articles (09/2003 - 03/2003)|
|9.||Banken, Ludger: 1 article (04/2004)|
|10.||Bellibas, S Eralp: 1 article (04/2004)|
09/20/2003 - "As compared to 5-ethynyluracil or 5-vinyluracil, which inhibited DPD not only in tumor tissues but also in other non-cancerous tissues, the effective dose range of RO0094889 in augmenting the efficacy of capecitabine was much broader. "
04/01/2004 - "Ro 09-4889 was designed to enhance the anticancer efficacy of capecitabine (Xeloda) by generating a dihydropyrimidine dehydrogenase inhibitor (DPDi) 5-vinyluracil (5-VU) preferentially in tumor tissues. "
09/20/2003 - "Administration of RO0094889 that is converted to a DPD inhibitor 5-vinyluracil selectively in tumor tissues restored the antitumor activity of capecitabine against the tumor of the HCT116 cells carrying DPD cDNA and various tumors expressing DPD. "
03/10/2003 - "RO0094889 (11c) is a prodrug of 5-vinyluracil (4c), a known DPD inhibitor, and was designed to generate 4c selectively in tumor tissues by sequential conversion of 11c by three enzymes: esterase, cytidine deaminase and thymidine phosphorylase, the latter two of which are known to be highly expressed in various tumor tissues. "
|1.||2',3'- O- diacetyl- 5'- deoxy- 5- vinylcytidine
|3.||Dihydrouracil Dehydrogenase (NADP) (Dihydropyrimidine Dehydrogenase)
|5.||Complementary DNA (cDNA)